Myelofibrosis

22 trials 9 recruiting MedDRA PT
22 Registered trials
9 Recruiting
16 Unique sponsors
21 Unique IMPs
20 Commercial trials
Drug classes (ATC)
— ATC code not specified 10
L Oncology (ATC L) 9
B Haematology (ATC B) 2
V Various (ATC V) 1
A Gastroenterology (ATC A) 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 11 substances
Kinase inhibitor 4 substances
Receptor fusion protein 2 substances
BCL-2 inhibitor 1 substance
JAK inhibitor 1 substance
Supportive / diluent 1 substance
Antimetabolite 1 substance
Phase III: 8 Phase II: 8 Phase I/II: 3 Phase I: 1 Phase I (Other): 2

Filter these 22 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 22 trials

Phase III

8 trials
  • Celgene Corp. Commercial
    LUSPATERCEPT
    2022-502498-40-00 8 countries 2019 n=139 Orphan
    Ended
  • Celgene Corp. Commercial
    LUSPATERCEPT; SODIUM CHLORIDE
    2023-507890-17-00 12 countries 2021 n=150 Orphan
    Ended
  • Celgene Corp. Commercial
    IMP not specified
    2024-511972-33-00 10 countries 2019 n=144
    Ended
  • Geron Corp. Commercial
    IMETELSTAT SODIUM
    2023-509120-17-00 11 countries 2021 n=260 Orphan
    Ended
  • Kartos Therapeutics Inc. Commercial
    LOPERAMIDE HYDROCHLORIDE; NAVTEMADLIN
    2023-504724-25-00 13 countries 2024 n=126
    Recruiting
  • Karyopharm Therapeutics Inc. Commercial
    APREPITANT; ONDANSETRON; PALONOSETRON, NETUPITANT; RUXOLITINIB
    2023-506139-13-00 13 countries 2024 n=195
    Ended
  • Merck Sharp & Dohme LLC Commercial
    BOMEDEMSTAT
    2023-506996-89-00 1 country 2024 n=25 Orphan
    Recruiting
  • Novartis Pharma AG Commercial
    PELABRESIB MONOHYDRATE; RUXOLITINIB
    2025-523555-66-00 9 countries n=173
    Pending

Phase II

8 trials
  • Glaxosmithkline Research & Development Limited Commercial
    MOMELOTINIB DIHYDROCHLORIDE MONOHYDRATE
    2023-508018-41-00 10 countries 2018 n=185 Orphan
    Ended
  • Incyte Corp. Commercial
    ITACITINIB
    2022-501661-47-00 6 countries 2023 n=12 Orphan
    Ended
  • Incyte Corp. Commercial
    RUXOLITINIB
    2023-507225-42-00 1 country 2024 n=6
    Recruiting
  • Karyopharm Therapeutics Inc. Commercial
    RUXOLITINIB
    2024-511309-47-00 13 countries 2024 n=38
    Recruiting
  • Karyopharm Therapeutics Inc. Commercial
    IMP not specified
    2024-513605-31-00 2 countries 2021 n=28
    Ended
  • Ryvu Therapeutics S.A. Commercial
    7,8-DIBROMO-5,6-DIHYDRO-9-METHYL-2-(1-PIPERAZINYL)-4H-IMIDAZO[4,5,1-IJ]QUINOLINE HYDROCHLORIDE; RUXOLITINIB
    2025-521673-14-00 4 countries 2025 n=29
    Recruiting
  • Takeda Development Center Americas Inc. Commercial
    ELRITERCEPT; RUXOLITINIB
    2023-507468-38-00 3 countries 2022 n=47
    Ended
  • Grupo Espanol De Enfermedades Mieloproliferativas Cronicas Ph Academic
    PACRITINIB
    2025-522509-39-00 1 country 2026 n=30
    Recruiting

Phase I/II

3 trials
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    2-(3-(3,5-DIMETHYLTRIAZOL-4-YL)-5-((S)-OXAN-4-YL(PHENYL)METHYL)PYRIDO(3,2-B)INDOL-7-YL)PROPAN-2-OL; RUXOLITINIB
    2023-509635-89-00 7 countries 2021 n=108
    Ended
  • Sumitomo Pharma America Inc. Commercial
    MOMELOTINIB DIHYDROCHLORIDE MONOHYDRATE; NUVISERTIB
    2022-502597-16-00 13 countries 2023 n=71 Orphan
    Recruiting
  • Martin-Luther-Universitaet Halle-Wittenberg Academic
    AZACITIDINE; FEDRATINIB
    2024-519227-22-00 1 country 2022 n=44 Orphan
    Ended

Phase I

1 trial
  • Ajax Therapeutics Inc. Commercial
    IMP not specified
    2025-522033-64-00 3 countries 2026 n=20
    Recruiting

Phase I (Other)

2 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    NAVITOCLAX; RUXOLITINIB
    2023-507274-40-00 6 countries 2021 n=60 Orphan
    Ended
  • Incyte Corp. Commercial
    IMP not specified
    2023-506145-38-00 3 countries 2021 n=44
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Incyte Corp. Commercial 3 Phase I (Other), Phase II 2
Karyopharm Therapeutics Inc. Commercial 3 Phase II, Phase III 1
Celgene Corp. Commercial 3 Phase III 0
Ajax Therapeutics Inc. Commercial 1 Phase I 1
AbbVie Deutschland GmbH & Co. KG Commercial 1 Phase I (Other) 0
Glaxosmithkline Research & Development Limited Commercial 1 Phase II 0
Ryvu Therapeutics S.A. Commercial 1 Phase II 1
Takeda Development Center Americas Inc. Commercial 1 Phase II 0
Geron Corp. Commercial 1 Phase III 0
Kartos Therapeutics Inc. Commercial 1 Phase III 1
Merck Sharp & Dohme LLC Commercial 1 Phase III 1
Novartis Pharma AG Commercial 1 Phase III 0
Bristol-Myers Squibb Services Unlimited Company Commercial 1 Phase I/II 0
Sumitomo Pharma America Inc. Commercial 1 Phase I/II 1
Grupo Espanol De Enfermedades Mieloproliferativas Cronicas Ph Academic 1 Phase II 1
Martin-Luther-Universitaet Halle-Wittenberg Academic 1 Phase I/II 0
New trials by year
2019
2
2021
6
2022
2
2023
2
2024
5
2025
1
2026
2
← All indication landscapes